{"id":"jak-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Elevated cholesterol"},{"rate":null,"effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JAK inhibitors work by inhibiting one or more of the four JAK family kinases (JAK1, JAK2, JAK3, TYK2), thereby suppressing the JAK-STAT signaling pathway. This pathway is critical for cytokine and growth factor signaling in immune and hematopoietic cells. By blocking JAK activity, these inhibitors reduce inflammatory cytokine production and immune cell activation, making them useful in both hematologic malignancies and inflammatory/autoimmune conditions.","oneSentence":"JAK inhibitors block Janus kinase enzymes, which are intracellular signaling proteins that transmit inflammatory and immune signals from cell surface receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:45.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, primary myelofibrosis)"},{"name":"Hematologic malignancies and related conditions"}]},"trialDetails":[{"nctId":"NCT06631287","phase":"PHASE3","title":"Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID","status":"RECRUITING","sponsor":"Wes Ely","startDate":"2024-10-21","conditions":"Long COVID, Sars-CoV-2 Infection, Coronavirus Infections","enrollment":550},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT07281456","phase":"PHASE2","title":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease","status":"RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2025-12-18","conditions":"Sjogren's Syndrome","enrollment":60},{"nctId":"NCT05104723","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-12","conditions":"Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease","enrollment":20},{"nctId":"NCT03874052","phase":"PHASE1","title":"Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Jennifer Saultz","startDate":"2019-08-16","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia","enrollment":51},{"nctId":"NCT07487311","phase":"","title":"A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-07","conditions":"Inflamatory Bowel Disease","enrollment":80},{"nctId":"NCT05452564","phase":"PHASE2","title":"Baricitinib for Reduction of HIV - CNS","status":"RECRUITING","sponsor":"William Tyor","startDate":"2023-05-18","conditions":"Human Immunodeficiency Virus","enrollment":95},{"nctId":"NCT06158113","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-03-13","conditions":"Lichen Planus, Oral, Lichen Planus, Mucosal, Oral Lichen Planus","enrollment":10},{"nctId":"NCT05387980","phase":"","title":"A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-04-19","conditions":"Atopic Dermatitis","enrollment":1128},{"nctId":"NCT07480824","phase":"PHASE1","title":"To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2026-04","conditions":"Myelofibrosis","enrollment":24},{"nctId":"NCT07447817","phase":"PHASE2","title":"Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias","status":"NOT_YET_RECRUITING","sponsor":"John Mascarenhas","startDate":"2026-05-04","conditions":"Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis","enrollment":26},{"nctId":"NCT06700499","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Akeso","startDate":"2024-07-08","conditions":"Atopic Dermatitis","enrollment":450},{"nctId":"NCT06150157","phase":"PHASE1","title":"A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-12-20","conditions":"Neoplasms","enrollment":220},{"nctId":"NCT07290803","phase":"","title":"This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-17","conditions":"Atopic Dermatitis","enrollment":1000},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":"Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome","enrollment":25},{"nctId":"NCT07387354","phase":"PHASE1, PHASE2","title":"Pacritinib With Aza for Upfront Myelodysplastic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2026-05","conditions":"Myelodysplastic Syndromes, MDS, Myelodysplastic Syndrome, Unclassifiable","enrollment":25},{"nctId":"NCT07469891","phase":"PHASE1","title":"A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Prelude Therapeutics","startDate":"2026-04","conditions":"Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs)","enrollment":100},{"nctId":"NCT06752694","phase":"PHASE2","title":"Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-25","conditions":"Aplastic Anemia","enrollment":20},{"nctId":"NCT02723994","phase":"PHASE2","title":"A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-30","conditions":"Leukemia","enrollment":171},{"nctId":"NCT05016297","phase":"PHASE2","title":"Efficacy and Safety of Baricitinib in Sjogren's Syndrome","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-14","conditions":"Sjogren's Syndrome","enrollment":87},{"nctId":"NCT07464951","phase":"PHASE1","title":"CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2026-04-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":30},{"nctId":"NCT04176198","phase":"PHASE1, PHASE2","title":"A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis","status":"RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2019-12-16","conditions":"Myelofibrosis","enrollment":240},{"nctId":"NCT04384692","phase":"PHASE2","title":"Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-12-18","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":53},{"nctId":"NCT07137598","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-12-05","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05530694","phase":"NA","title":"Rheumatoid Arthritis Shared Decision Making","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2022-09-19","conditions":"Rheumatoid Arthritis","enrollment":900},{"nctId":"NCT07448363","phase":"","title":"Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)","enrollment":50},{"nctId":"NCT07443306","phase":"PHASE2","title":"A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2026-04-30","conditions":"MF","enrollment":64},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT06660355","phase":"PHASE2","title":"Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-12-23","conditions":"Chronic Graft-versus-host Disease (cGVHD)","enrollment":120},{"nctId":"NCT07028385","phase":"PHASE2","title":"Safety and Impact of Baricitinib on Cell Surivival Pathways, HIV-1 Reservoir and Inflamation in People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-09-22","conditions":"HIV","enrollment":30},{"nctId":"NCT06905288","phase":"","title":"Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-02","conditions":"Ankylosing Spondylitis","enrollment":70},{"nctId":"NCT07025538","phase":"PHASE1","title":"Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2026-03-09","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":42},{"nctId":"NCT07209267","phase":"PHASE2","title":"Baricitinib Curative Repression of HIV-1","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"HIV Infection, HIV","enrollment":20},{"nctId":"NCT07228624","phase":"PHASE2","title":"Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-02-04","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":50},{"nctId":"NCT06241118","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-02-29","conditions":"Dermatitis Atopic","enrollment":390},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT07406035","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":"Psoriatic Arthritis","enrollment":156},{"nctId":"NCT07406204","phase":"PHASE4","title":"Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)","status":"NOT_YET_RECRUITING","sponsor":"Hayat Abad Medical Complex, Peshawar","startDate":"2026-02-15","conditions":"Alopecia Areata, Alopecia Totalis (AT), Alopecia Universalis","enrollment":78},{"nctId":"NCT05980806","phase":"PHASE2","title":"A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2024-04-22","conditions":"Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia","enrollment":58},{"nctId":"NCT03954236","phase":"PHASE2","title":"Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-05-14","conditions":"Non-sclerotic Cutaneous Chronic Graft-versus-host Disease","enrollment":24},{"nctId":"NCT05651880","phase":"PHASE3","title":"Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03","conditions":"Active Non-anterior Non-infectious Uveitis","enrollment":33},{"nctId":"NCT05592015","phase":"PHASE2","title":"Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Jonathan Brammer","startDate":"2023-05-03","conditions":"T-Cell Large Granular Lymphocyte Leukemia","enrollment":30},{"nctId":"NCT06868381","phase":"PHASE2","title":"A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-04-01","conditions":"Cardiac Sarcoidosis","enrollment":10},{"nctId":"NCT05037760","phase":"PHASE2","title":"A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis","status":"RECRUITING","sponsor":"Takeda","startDate":"2021-12-16","conditions":"Myelofibrosis","enrollment":135},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT07357727","phase":"PHASE3","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-04-15","conditions":"Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)","enrollment":460},{"nctId":"NCT06240351","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-04-22","conditions":"Frontal Fibrosing Alopecia","enrollment":15},{"nctId":"NCT06976918","phase":"","title":"Registry Platform Myelofibrosis and Anemia","status":"NOT_YET_RECRUITING","sponsor":"iOMEDICO AG","startDate":"2026-03","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":200},{"nctId":"NCT06688838","phase":"","title":"Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Tongji Hospital","startDate":"2017-01-01","conditions":"Blau Syndrome","enrollment":24},{"nctId":"NCT04217356","phase":"","title":"Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-05","conditions":"Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer","enrollment":90},{"nctId":"NCT07368673","phase":"PHASE4","title":"Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Dow University of Health Sciences","startDate":"2025-04-06","conditions":"Vitiligo","enrollment":120},{"nctId":"NCT03222609","phase":"PHASE2","title":"A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-10-31","conditions":"Myelofibrosis (MF)","enrollment":191},{"nctId":"NCT06887803","phase":"PHASE1, PHASE2","title":"A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors","status":"RECRUITING","sponsor":"iOnctura","startDate":"2025-11-17","conditions":"Myelofibrosis (MF)","enrollment":26},{"nctId":"NCT07336641","phase":"","title":"LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice","status":"NOT_YET_RECRUITING","sponsor":"Fondazione ISIDE","startDate":"2026-01","conditions":"Psoriasis, Atopic Dermatitis, Vitiligo","enrollment":20000},{"nctId":"NCT07219576","phase":"PHASE1, PHASE2","title":"Retifanlimab and Ruxolitinib In Solid Malignancies","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2026-01-08","conditions":"Non Small Cell Lung Carcinoma, Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT04370301","phase":"PHASE2","title":"Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-02-09","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":20},{"nctId":"NCT06008808","phase":"PHASE1","title":"Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-07","conditions":"Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease","enrollment":41},{"nctId":"NCT05371964","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis","status":"RECRUITING","sponsor":"Geron Corporation","startDate":"2022-05-04","conditions":"Myelofibrosis","enrollment":36},{"nctId":"NCT06245941","phase":"PHASE1, PHASE2","title":"A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)","status":"TERMINATED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-05-13","conditions":"Myelofibrosis","enrollment":21},{"nctId":"NCT03921554","phase":"PHASE2","title":"JAK Inhibitor Treatment in AGS","status":"COMPLETED","sponsor":"Adeline Vanderver, MD","startDate":"2019-06-03","conditions":"Aicardi Goutieres Syndrome","enrollment":54},{"nctId":"NCT05063110","phase":"PHASE2","title":"Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIB","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-03","conditions":"Adults Patients Having Non Severe HLH","enrollment":35},{"nctId":"NCT06490757","phase":"PHASE2","title":"A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-02","conditions":"Inflammatory Hepatocellular Adenoma","enrollment":25},{"nctId":"NCT05393674","phase":"PHASE2","title":"Fedratinib in Combination With Nivolumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2022-06-14","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":30},{"nctId":"NCT03801434","phase":"PHASE2","title":"Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","status":"RECRUITING","sponsor":"William Shomali","startDate":"2019-11-15","conditions":"BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells","enrollment":10},{"nctId":"NCT07293390","phase":"PHASE1","title":"A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-03-18","conditions":"Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects","enrollment":6},{"nctId":"NCT04496960","phase":"PHASE1, PHASE2","title":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2021-05-18","conditions":"Sjogren's Syndrome","enrollment":23},{"nctId":"NCT03654768","phase":"PHASE2","title":"Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-10-24","conditions":"Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":81},{"nctId":"NCT06541249","phase":"PHASE2","title":"MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2024-10-02","conditions":"Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)","enrollment":54},{"nctId":"NCT04603495","phase":"PHASE3","title":"Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-09","conditions":"Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":430},{"nctId":"NCT07283822","phase":"PHASE2","title":"Amping up With PemJAK","status":"RECRUITING","sponsor":"Seda S. Tolu","startDate":"2025-12-03","conditions":"Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed","enrollment":53},{"nctId":"NCT06615050","phase":"PHASE3","title":"A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-04-02","conditions":"Graft-versus-host Disease (GVHD)","enrollment":572},{"nctId":"NCT06517875","phase":"PHASE2","title":"Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-02-28","conditions":"Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","enrollment":56},{"nctId":"NCT06024915","phase":"PHASE1","title":"A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-09-21","conditions":"Myelofibrosis","enrollment":40},{"nctId":"NCT04246372","phase":"PHASE2","title":"Tofacitinib for Immune Skin Conditions in Down Syndrome","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-10-21","conditions":"Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema","enrollment":47},{"nctId":"NCT06627335","phase":"","title":"An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-03-27","conditions":"Pregnancy Related, Atopic Dermatitis","enrollment":5621},{"nctId":"NCT06259669","phase":"","title":"Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2023-09-13","conditions":"Pregnancy Related, Atopic Dermatitis","enrollment":958},{"nctId":"NCT07272850","phase":"","title":"Comparison Between JAK Inhibitors and Traditional Treatment of Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-12-20","conditions":"Rheumatoid Arthritis, Arthritis","enrollment":72},{"nctId":"NCT06682169","phase":"PHASE3","title":"Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Graft-versus-host Disease","enrollment":182},{"nctId":"NCT06122831","phase":"PHASE1, PHASE2","title":"A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-12-12","conditions":"Myelofibrosis","enrollment":92},{"nctId":"NCT06616155","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-01-30","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":39},{"nctId":"NCT05689151","phase":"","title":"A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-03-09","conditions":"Atopic Dermatitis, Eczema","enrollment":183},{"nctId":"NCT07268534","phase":"PHASE2","title":"Biologics in Folliculitis Decalvans : an Adaptative Trial Research","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Folliculitis Decalvans (FD)","enrollment":120},{"nctId":"NCT05955066","phase":"PHASE4","title":"Effect of JAK Inhibitor on Erosion Healing in RA","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-12-01","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02251821","phase":"PHASE2","title":"JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2014-10-20","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":61},{"nctId":"NCT04576156","phase":"PHASE3","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geron Corporation","startDate":"2021-04-12","conditions":"Myelofibrosis","enrollment":327},{"nctId":"NCT07261891","phase":"NA","title":"Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders","status":"RECRUITING","sponsor":"prof. dr. Rik Schrijvers","startDate":"2024-11-21","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":20},{"nctId":"NCT07261306","phase":"EARLY_PHASE1","title":"Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis","status":"RECRUITING","sponsor":"Lahore General Hospital","startDate":"2025-08-29","conditions":"Psoriasis","enrollment":75},{"nctId":"NCT04944043","phase":"PHASE1, PHASE2","title":"A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-06-25","conditions":"Chronic Graft Versus Host Disease","enrollment":45},{"nctId":"NCT03760003","phase":"PHASE2","title":"Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-08-13","conditions":"Ulcerative Colitis","enrollment":355},{"nctId":"NCT07211932","phase":"","title":"Tofacitinib in Juvenile Idiopathic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Consorci Sanitari de l'Alt Penedès i Garraf","startDate":"2025-12","conditions":"Juvenile Idiopathic Arthritis (JIA)","enrollment":58},{"nctId":"NCT07012057","phase":"PHASE2","title":"Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis","status":"WITHDRAWN","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2025-11-21","conditions":"Myositis, Dermatomyositis","enrollment":""},{"nctId":"NCT04581954","phase":"PHASE1, PHASE2","title":"Inflammatory Signal Inhibitors for COVID-19 (MATIS)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2020-10-02","conditions":"Coronavirus, Covid19, Pneumonia","enrollment":185},{"nctId":"NCT06020014","phase":"PHASE2","title":"Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-16","conditions":"Asthma","enrollment":339},{"nctId":"NCT04744116","phase":"EARLY_PHASE1","title":"Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease","enrollment":24},{"nctId":"NCT04239989","phase":"PHASE1","title":"Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-08","conditions":"Bronchiolitis Obliterans","enrollment":8},{"nctId":"NCT06715982","phase":"PHASE2","title":"JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial","status":"RECRUITING","sponsor":"Shixiu Wu","startDate":"2024-12-31","conditions":"Immune Checkpoint Inhibitors (ICI)-Related Dermatitis","enrollment":35},{"nctId":"NCT06238817","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-04-26","conditions":"Atopic Dermatitis","enrollment":241},{"nctId":"NCT06435273","phase":"PHASE2","title":"Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-05","conditions":"Asthma","enrollment":36},{"nctId":"NCT03320642","phase":"PHASE1","title":"GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2018-02-27","conditions":"Hematologic Malignancies","enrollment":84}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"GASTRIC ULCER"},{"count":1,"reaction":"GASTROINTESTINAL HAEMORRHAGE"},{"count":1,"reaction":"PYREXIA"}],"_approvalHistory":[],"publicationCount":2847,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JAK inhibitors","Janus Kinase Inhibitor","Ruxolitinib","Fedratinib","Tofacitinib, baricitinib, or upadacitinib"],"phase":"marketed","status":"active","brandName":"JAK Inhibitor","genericName":"JAK Inhibitor","companyName":"Fred Hutchinson Cancer Center","companyId":"fred-hutchinson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JAK inhibitors block Janus kinase enzymes, which are intracellular signaling proteins that transmit inflammatory and immune signals from cell surface receptors. Used for Myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, primary myelofibrosis), Hematologic malignancies and related conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":8,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}